Avax One Technology Ltd. (AVX) Q1 2026 Earnings Call Transcript
Avax One Technology Ltd. (AVX) Q1 2026 Earnings Call Transcript
seekingalpha.com
LCTX(LCTX)
LCTX
Next earnings: Aug 11, 2026 · After close
Signal
Bearish Setup2↓
PRICE
Prev Close
1.31
Open
1.26
Day Range1.23 – 1.28
1.23
1.28
52W Range0.45 – 2.09
0.45
2.09
49% of range
VOLUME & SIZE
Avg Volume
1.2M
FUNDAMENTALS
P/E Ratio
-4.3x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
0.98
Market-like
Performance
1D
-4.58%5D
-9.42%1M
-23.31%3M
-24.70%6M↓
-33.51%YTD
-25.15%1Y↑
+165.67%Best: 1Y (+165.67%)Worst: 6M (-33.51%)
Quick Read
Trend—Insufficient MA data
Momentum
BULLISH
revenue +55% YoY · 98% gross marginValuation
FAIR
P/E not availableHealth
MODERATE
CR 6.9 · FCF negativeBullish
Key MetricsTTM
Market Cap$311.62M
Revenue TTM$14.78M
Net Income TTM-$64.21M
Free Cash Flow-$22.30M
Gross Margin98.0%
Net Margin-434.4%
Operating Margin-255.1%
Return on Equity-152.1%
Return on Assets-58.6%
Debt / Equity0.04
Current Ratio6.89
EPS TTM$-0.26
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
3 strong3 concern
50/100Liquidity
6.89Strong
Leverage
0.04Strong
Coverage
0.0xConcern
ROE
-152.1%Concern
ROIC
-34.1%Concern
Cash
$41MStrong
ANALYST COVERAGE5 analysts
BUY
Stock Health
Composite Score
2 of 5 signals bullish
3/10
Technicals
●
✗RSI RangeRSI 30 — Bearish momentum
Volume
●
✗Volume FlowDistribution — institutional selling
Fundamentals
●
✗Last EarningsMissed estimates
●
✓Analyst ConsensusBuy
●
✓LiquidityCurrent Ratio 6.89 — healthy liquidity
Upcoming Events
EEarnings ReportMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentSep 10, 2026
In 117 days
FinancialsFull statements →
Technicals
Technical SetupBEARISH
Technicals →Trend
▼ DowntrendGolden Cross · 50D leads 200D by 7.9%
-23.1% vs SMA 50 · -17.0% vs SMA 200
Momentum
RSI30.3Momentum fading
MACD-0.10Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$2.09+67.2%
EMA 50
$1.56+24.7%
EMA 200
$1.43+14.1%
Current
$1.25
52W Low
$0.4500-64.0%
52-Week RangeMid-range
$0.450049th %ile$2.09
Squeeze SetupVolume-based
Distribution PressureHeavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.
20-Day Money Flow
Acc days:5
Dist days:5
Edge:Even
Volume Context
Avg Vol (50D)1.3M
Recent Vol (5D)
1.6M+31%
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 5 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $9.9M $9.1M–$10.6M | — | -$0.30 | — | ±47% | High5 |
FY2026(current) | $15.6M $7.3M–$24.4M | ▲ +57.9% | -$0.07 | — | ±31% | High5 |
FY2027 | $11.0M $2.9M–$22.8M | ▼ -29.7% | -$0.09 | — | ±50% | High5 |
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryLCTX
Last 8Q
-47.4%avg beat
Beat 4 of 8 quartersMissed 3↑ Estimates rising+40%
Q3'24
-53%
Q4'24
+75%
Q1'25
—
Q2'25
+50%
Q3'25
-550%
Q4'25
+109%
Q1'26
-50%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced heightInsider Activity
SEC Filings →6 Buys/0 SellsNet Buying
Culley Brian MDir
$24K
Mar 12
BUY
Broadwood Partners,…Dir
$6.0M
Jan 27
BUY
Broadwood Partners,…Dir
$0
Jan 27
BUY
Broadwood Partners,…Dir
$0
Jan 27
BUY
Howe Jill AnnCFO
$9K
Nov 26
BUY
Samuel George A. IiiGeneral Counsel
$9K
Nov 26
BUY
Financials
INSTITUTIONAL OWNERSHIP
1
Defender Capital, LLC.
6.7M▼2
FIFTH THIRD BANCORP
4.6M▲3
BlackRock, Inc.
3.9M▲4
RENAISSANCE TECHNOLOGIES LLC
2.1M▼5
UBS Group AG
1.4M▲6
VANGUARD FIDUCIARY TRUST CO
1.3M▲7
JANE STREET GROUP, LLC
993K▼8
RED CRANE WEALTH MANAGEMENT, LLC
597K—News & Activity
LCTX News
19 articles · 4h ago
EUFN: European Financials Remain Attractively Valued Ahead Of Potential Rate Hikes
seekingalpha.com
U.S. Global Investors' Frank Holmes on why travel stocks look undervalued - ICYMI
proactiveinvestors.com
Kyivstar Group Ltd. (KYIV) Q1 2026 Earnings Call Transcript
seekingalpha.com
BMW's Wild Vision K 18 Concept Looks Ready for Blade Runner
youtube.com
BlackRock weighs multibillion-dollar investment in SpaceX IPO, the Information reports
reuters.com
Orbit Garant Drilling Q3 Earnings Call Highlights
marketbeat.com
Onex Q1 Earnings Call Highlights
marketbeat.com
Pollard Banknote Q1 Earnings Call Highlights
marketbeat.com
Pet Valu Q1 Earnings Call Highlights
marketbeat.com
Peyto Exploration & Development Q1 Earnings Call Highlights
marketbeat.com
Parex Resources Q1 Earnings Call Highlights
marketbeat.com
Quebecor Q1 Earnings Call Highlights
marketbeat.com
Quarterhill Q1 Earnings Call Highlights
marketbeat.com
Gen Z shoppers helping revive America’s malls with push for in-person experiences
foxbusiness.com
Studies Highlight Advances in Kidney Stone Prevention and Anesthesia Free Stone Removal
globenewswire.com
Kolter Urban Selects FirstService Residential to Manage Art House St. Petersburg
prnewswire.com
KinderCare Learning Companies, Inc. (KLC) Q1 2026 Earnings Call Transcript
seekingalpha.com
Seagate and Western Digital: AI Storage Demand Is Now Showing Up in Pricing Power
247wallst.com
About
biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Brian Culley
Website
Charlotte HubbertVice President of Corporate Strategy & Development
Brian CulleyChief Executive Officer, President & Director
Harold D. WaitzVice President of Regulatory Affairs & Quality Control
Peers— —(7 companies)
Screen sector →| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
LCTX◀ | $1.25 | -4.58% | $312M | — | +5323.7% | -43647.3% | 1500 |
| $404.35 | -3.20% | $2.1T | 30.5 | +3296.8% | 4510.0% | 1500 | |
| $132.58 | -6.05% | $307.9B | 20.7 | -44.8% | 1012.0% | 1500 | |
| $88.38 | -2.58% | $303.7B | 13.6 | +318.8% | 1510.7% | 1500 | |
| $148.08 | -1.13% | $282.6B | 21.0 | +597.3% | 2564.4% | 1500 | |
| $181.58 | -1.83% | $281.6B | 26.9 | +862.9% | 1745.9% | 1500 | |
| $183.40 | -0.23% | $256.1B | 16.8 | +213.3% | 1482.4% | 1500 | |
| Sector avg | — | -2.80% | — | 21.6 | +1509.7% | -4403.1% | 1500 |